Vertex's Symdeko approved for young patients with cystic fibrosis | FDA OKs drug to boost sexual desire in premenopausal women | FDA approves Ocular sNDA for Dextenza
June 24, 2019
Bio SmartBrief
SIGN UP ⋅   FORWARD
Today's Top Story
Vertex's Symdeko approved for young patients with cystic fibrosis
Vertex Pharmaceuticals received FDA approval for its Symdeko tablets, a formulation of tezacaftor and ivacaftor, for treatment of pediatric patients ages 6 and older with cystic fibrosis who have certain genetic profiles. Studies found that the safety profile of the drug in patients as young as 6 mirrors the safety profile seen in older children.
Medscape (free registration) (6/21) 
LinkedIn Twitter Facebook Email
Health Care & Policy
FDA OKs drug to boost sexual desire in premenopausal women
The FDA has approved Vyleesi, a treatment developed by Amag Pharmaceuticals and Palatin Technologies to restore sexual desire in premenopausal women. Amag will give Palatin $60 million for the regulatory decision and additional payments for milestones and royalties.
Reuters (6/21) 
LinkedIn Twitter Facebook Email
FDA approves Ocular sNDA for Dextenza
The supplemental new drug application for the use of Ocular Therapeutix's Dextenza, or dexamethasone ophthalmic insert, as a treatment of ocular inflammation after opthalmic surgery has been approved by the FDA. The decision was backed by late-stage trials in which more patients experienced no pain eight days after treatment with Dextenza and demonstrated a statistically significant lack of anterior chamber cells versus the vehicle group 14 days after treatment.
eMPR (6/21) 
LinkedIn Twitter Facebook Email
Allergan secures FDA nod for Botox in pediatric cerebral palsy
The FDA has approved Allergan's supplemental biologics application for Botox as a treatment for children two to 17 years old with upper limb spasticity.
The Irish Times (Dublin) (6/24) 
LinkedIn Twitter Facebook Email
Updated data reported for Dicerna's primary hyperoxaluria candidate
Dicerna Pharmaceuticals unveiled updated results from an ongoing early-stage trial assessing the safety, efficacy and tolerability of its experimental drug DCR-PHXC in patients with type 1 or type 2 primary hyperoxaluria. The data, which showed patients experiencing substantial 24-hour reductions in urinary oxalate levels after administration of a single-dose of DCR-PHXC, were presented during the Oxalosis & Hyperoxaluria Foundation International Hyperoxaluria Workshop.
Seeking Alpha (6/21) 
LinkedIn Twitter Facebook Email
Hyperkalemia drug beneficial to dialysis patients with ESRD
Data shows that AstraZeneca's Lokelma, or sodium zirconium cyclosilicate, was effective in treating patients with end-stage renal disease who have hyperkalemia and are undergoing hemodialysis. Findings were presented at the 56th Congress of the European Renal Association-European Dialysis and Transplant Association and were also published in the Journal of the American Society of Nephrology.
Medscape (free registration) (6/21) 
LinkedIn Twitter Facebook Email
Company & Financial News
Sites chosen for international trial of CMV vaccine candidate
Hookipa Pharma will fund a clinical trial for its investigational vaccine HB-101 for the prevention of cytomegalovirus infections in patients who undergo kidney transplants. The University of Cincinnati Medical Center will serve as one of an estimated 40 international test sites that will enroll a total of 150 transplant patients.
Precision Vaccinations (6/21) 
LinkedIn Twitter Facebook Email
4 life sciences startups launch IPOs
Life sciences startups had a big day of initial public offerings on Wednesday. The genome sequencing and analysis platform Personalis raised $134 million; biotech Akero Therapeutics raised about $92 million; gene therapy developer Prevail Therapeutics raised $125 million; and immune therapy developer Atreca raised $113.8 million.
Xconomy (6/20) 
LinkedIn Twitter Facebook Email
The Latest From BIO ...
There is no charge for member companies to use the BIO Business Solutions®, and companies can take advantage of one or all of the special pricing arrangements offered through the program. See what we can do for you!
LinkedIn Twitter Facebook Email
Learn more about BIO:
Conferences | Join Bio | Media | Issues | Industry
Food & Agriculture
Crop Life exhibits benefits of biotech maize
The Crop Life Pakistan Association exhibited the benefits of biotechnology through the performance of maize hybrids in the field and highlighted its importance in cultivation during a value assessment trial.
Online International News Network (Pakistan) (6/22) 
LinkedIn Twitter Facebook Email
Hot Topics
Industrial & Environmental
Trump seeks revisions to EPA's expanded biofuel waiver program
President Donald Trump has reportedly instructed cabinet members to explore changes to the Environmental Protection Agency's biofuel waiver program for oil refiners in response to complaints from the ethanol industry. The EPA has issued four times the number of small refinery waivers since Trump became president, upsetting corn farmers.
Reuters (6/20) 
LinkedIn Twitter Facebook Email
News From BIO
Savings on environmental waste disposal services
BIO has partnered with Clean Harbors, a worldwide leader in waste management and environmental services, to offer members a full range of hazardous and nonhazardous materials management and disposal services with deep discounts: 35%-40% off list on disposal, 15%-20% off list on transportation and materials, and 35% off list price on labor charges. In addition, the BIO-Clean Harbors program offers full online tracking, free site visits to assure compliance with state and federal laws, and staff training support at no additional charge. Learn more!
LinkedIn Twitter Facebook Email
Learn more about BIO:
Conferences | Join Bio | Media | Issues | Industry
  
  
If I fail, I'm coming back. If I fail again, I'm coming back stronger.
Devean George,
former NBA player
LinkedIn Twitter Facebook Email
  
  
The news summaries appearing in BIO SmartBrief are based on original information from news organizations and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The information is not compiled or summarized by BIO. Questions and comments should be directed to SmartBrief at bio@smartbrief.com.
Sign Up
SmartBrief offers 200+ newsletters
Advertise
Learn more about the SmartBrief audience
Subscriber Tools:
Contact Us:
Advertising  -  Sarah Hostetler
Editor  -  Nicole Brown
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2019 SmartBrief, Inc.®
Privacy Policy (updated May 25, 2018) |  Legal Information